AstraZeneca Exanta Risk Plan Not Sufficient To Allay Liver Toxicity Concerns
Executive Summary
AstraZeneca's proposed Exanta risk management plan is not sufficient to alleviate liver toxicity concerns with the anticoagulant, FDA's Cardiovascular & Renal Drugs Advisory Committee said
You may also be interested in...
Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.
AstraZeneca's Exanta should demonstrate more definitive superiority to Bristol-Myers Squibb's Coumadin (warfarin) prior to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed
Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.
AstraZeneca's Exanta should demonstrate more definitive superiority to Bristol-Myers Squibb's Coumadin (warfarin) prior to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed
Last rites for the first glitazone
FDA withdraws approval for NDA for Pfizer's Rezulin (troglitazone), a notice in the Jan. 10 Federal Register states. Pfizer withdrew the NDA for the diabetes drug after the product was pulled from the market in 2000 following 90 cases of acute liver damage, including 63 deaths (1"The Pink Sheet" March 27, 2000, p. 4)...